With every passing day, new discoveries are made that lend support to the increasing and important role biomarker analysis and tumor profiling play in personalized cancer care. Caris Life Sciences® is actively participating in research to advance the understanding of molecular science, further enabling the delivery of precision medicine.

2018 American Society of Clinical Oncology (ASCO)

Pathogenic somatic mutation (SM) of mismatch repair (MMR) genes and associations with microsatellite instability (MSI), tumor mutational burden (TMB) and SM in other DNA repair pathways in 24,223 tumor genomic profiles

Circadian clock gene PER1 mutations in colorectal cancer (CRC)Incidence of Neuregulin1 (NRG1) gene fusions across tumor types

Comprehensive molecular profiling of paired patient samples of primary and metastatic (met) pancreatic ductal adenocarcinoma (PDAC)

Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults (AYA) with Colorectal Cancer (CRC)

Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC)

Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Impact of MLH1, PMS2, MSH2 and MSH6 alterations on tumor mutation burden (TMB) and PD-L1 expression in 1,057 microsatellite instability-high (MSI-H) tumors

Mutational Complexity Increases in Lung Adenocarcinoma (LADC) with the Development of Brain Metastasis (BM)

Multi-omic Profiling of Metastatic Lesions to Guide Treatment Selection: The Side Out 2 Trial Experience Associations of age, PD-L1 status, BRAF mutation and TMB in advanced melanoma.

2018 Society of Gynecologic Oncology (SGO)

Molecular Variations in Uterine Carcinosarcomas: Are There Therapeutic Opportunities?

Mutational burden, tumor PDL-1 expression, and microsatellite instability in gynecologic malignancies: Implications for immune therapy

Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer

Distinct molecular profiles and potential therapeutic targets in androgen receptor stratified ovarian cancer patients

2018 Gastrointestinal Cancers Symposium (ASCO-GI)

Molecular Characterization of Intestinal and Diffuse Types of Gastric Cancer

Differences in Molecular Profiles of Males and Females with Colorectal Cancer (CRC)

2018 Gastrointestinal Cancers Symposium (ASCO-GU)

Molecular profiles of small cell bladder and prostate cancer, comparisons with small cell lung cancer

A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)

2017 American Society of Clinical Oncology (ASCO)

Impact of patient age on molecular alterations in left-sided colorectal tumors

Molecular profiling comparison of breast cancer subtypes in young women and older women

Variable DNA mismatch repair associated gene profiles in colorectal versus uterine cancers

Characterization of Tumor Mutation Load (TML) in Solid Tumors

Distribution of Receptor Tyrosine Kinase (RTK) nsSNPs in Breast Cancer (BC) Patients using Next-Generation Sequencing (NGS)

Spectrum of Tumor Mutational Load in Genitourinary Cancers

Colorectal cancer: impact of primary tumor location on genetic alterations

Prevalence of Homologous Recombination Deficiency (HRD) Among All Tumor Types

Localization of Non-Receptor Tyrosine Kinase (nRTK) Variants in Solid Tumor Patients Using Next-Generation Sequencing (NGS)

RNASeq Analysis of Glioma Tumors reveal Targetable Gene Fusions

2017 Gastrointestinal Cancers Symposium (ASCO-GI)

Molecular Variances Between Rectal and Left Sided Colon Cancers

Molecular characterization of squamous cell carcinoma of the anal canal (SCCA)


Characterization of Tumor Mutation Burden (TMB) in Gastrointestinal (GI) Cancers.

2016 San Antonio Breast Conference

Racial differences in the molecular landscape of breast cancer 
Programmed death 1 (PD-1) and PD-1 ligand (PD-L1) distribution in triple negative breast cancer TNBC
ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors

2016 Society for Neuro-Oncology (SNO)

Medulloblastoma candidate pathways for novel treatment strategies
Novel targets in ependymal tumors
PD-1,PD-L1 and genomic expression profiling of meningiomas 

2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Comparative molecular analyses of BRAF-V600E mutant tumors: Colorectal cancers (CRC) vs. melanomas
Comparative molecular analyses of colon versus rectal tumors
Ras family mutation patterns in a large cohort of CRCs
Comparative molecular analyses of esophageal cancer: Adenocarcinoma vs. squamous cell carcinomas and impact on outcome
Use of panomic assessment to reveal DNA repair alterations and to predict potential therapeutic response to taxane-platinum combination therapy in prostate cancer
Differences in the molecular landscape of cancer between African American (AA) and Caucasian (CC) cancer patients
Novel panomic validation of time to next treatment (TNT) as an effective surrogate outcome measure in 4,729 patients
Comparative molecular analyses of pancreatic cancer (PC): KRAS wild type vs. KRAS mutant tumors and primary tumors vs. distant metastases
Distribution of PD-L1 expression in diverse cancer types: Experience with over 10,000 cases 
Fusion analysis of solid tumors to reveal novel rearrangements in breast carcinomas
Tumor profiling of liver metastases (LM) from CRC, NSCLC, pancreatic (PC), breast (BC) and gastroesophageal (GE) tumors to reveal differences versus primary tumors including in cMET, MYC, CDK4, Her2, b-catenin and PD1

2016 American Association for Cancer Research  (AACR) 

Multiplatform molecular profiling of invasive lobular breast cancer 
Molecular and genomic characterization of SCLC 
Clinico-pathological and molecular features associated with TP53 mutation in 3457 molecularly-profiled colorectal cancers (CRCs) 
Frequent BRCA2 somatic mutations in colorectal cancer patients with mircrosatellite instability (MSI) 
Mutations on the homologous recombination pathway in 13 cancer types 
Expression of class III beta-tubulin (TUBB3) in 3580 colorectal cancers (CRCs) and correlation with clinico-pathological and molecular features
A rationale for treatment of colorectal cancer with mitomycin C and crizotinib 
Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH) 

2016 Society of Gynecologic Oncology (SGO)

Multiplatform tumor-profiling of 50 malignant Sertoli-Leydig cell tumors of the ovary reveals therapeutic 

2016 Gastrointestinal Cancers Symposium (ASCO-GI)

Molecular characterization of colorectal tumors in young patients compared with older patients and impact on outcome 

2016 Genitourinary Cancers Symposium (ASCO – GU)

Molecular profiling of non-urothelial bladder cancer: adenocarcinoma and squamous cell carcinoma 


Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

Identification of molecular targets in vulvar cancers

Comparative molecular profiling of HPV-induced squamous cell carcinomas

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations